Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a non-Hodgkin lymphoma subtype that varies patient by patient, with some having a highly aggressive disease course and others having indolent disease that progresses slowly over several years.

This AMCP and AMCP Foundation webinar reviewed the complexities of real-world evidence and its increasingly important role in health care decision-making.

AMCP Webinar that looked at the most critical evidentiary gaps for the field of managed care pharmacy.

A retrospective claims data analysis published in JMCP found that patients with metastatic melanoma treated with PD-1 had substantially lower costs than patients treated with other first line agents.

A retrospective claims data analysis published in JMCP found that patients with metastatic melanoma treated with PD-1 had substantially lower costs than patients treated with other first line agents.

A cost impact analysis of Medicare patients with Alzheimer's disease and dementia in their final years of life found that families and Medicaid bear the bear most of the cost burden. The authors of this JMCP article propose the need to better integrate Medicare and Medicaid to fund and improve patient outcomes.

Patients with treatment resistant depression use more resources and have significantly higher health care costs, according to a retrospective cohort published in JMCP.